Premier Energies Q2 FY27 Earnings Call: Order Book Hits Rs. 16,260 Cr, 7 GW Cell Line Commissioned (PREMIERENE)

Premier Energies Ltd held its Q2 FY27 earnings call on November 04, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Steady Quarter with Double-Digit Growth Across the P&L

• Revenue up 38.2% YoY to Rs.2,656 crore — Q2 FY 2026-2027 consolidated actuals; EBITDA up 17.8% YoY to Rs.760 crore and PAT up 30.8% YoY to Rs.462 crore.
• Solar manufacturing margins at 29.3% EBITDA / 17.9% PAT — PAT margin moderated slightly by higher depreciation and lower other income.
• Transcon subsidiary posted Rs.122 crore revenue and Rs.18 crore PAT — EBITDA margin of 15% and PAT margin of 8% in Q2 FY 2026-2027.
• Record capacity utilization — operational cell plants delivered record utilization in Q2 FY 2026-2027; management characterized the quarter as "another quarter of steady performance" in a challenging macro.
• Inventory buildup is raw-material-led — driven by advance stocking for the Chittarampur ramp-up, the newly commissioned Naidupeta plant, and war-related delivery delays/port congestion; management expects normalization latest by Q4 FY 2026-2027.
• Balance sheet strength cited — low cost of capital and an A+ credit rating positioned as key pillars of competitiveness.

Rs.16,260 Cr Book, Premium Non-DCR Realizations, DCR Discipline

• Rs.4,001 crore of new cell-and-module order wins in Q2 FY 2026-2027 — in a highly competitive market, taking the total order book to Rs.16,260 crore (management cited ~Rs.16,000–16,500 crore across the call).
• ~68-70% of the order book is domestic/DCR — cell and module businesses are each ~48% of the total; ~20% of the module business is DCR; retail constitutes roughly 35-40% of the order book.
• Non-DCR module pricing at Rs.12.75-13/watt — Premier is realizing Rs.12.75 and above while market participants accept sub-Rs.12 orders; the MD attributed the premium to high-quality automated lines. Non-DCR pricing has fallen from Rs.14-15/Wp earlier in FY 2026-2027 to about Rs.12.5/Wp currently, impacting non-DCR margins.
• DCR module realizations: retail Rs.23-24/watt, Kusum C & C&I ~Rs.21.5/watt, large IPP Rs.20.5-20/watt — blended average ~Rs.21.5-22/watt (Q2 FY 2026-2027 snapshot); the IPP pricing is for FY 2027-2028 deliveries as IPPs plan well in advance.
• Rs.18 DCR quote rejected as a benchmark — management said a peer's SECI DCR tender win at ~Rs.17-18 was an introductory offer to fill ~10-15% of the winner's line capacity, not reflective of market pricing; reiterated IPP market prices for FY 2027-2028 remain around Rs.20.
• DCR cell prices at 12-14 cents in Q2 FY 2026-2027 — MonoPERC ~12-12.5 cents, TopCon ~14-14.5 cents.

7 GW Cell Line Commissioned; Wafer Plant on Track for 2027-2028

• 7 GW TOPCon cell line commissioned at Naidupeta — trial runs underway with commercial production expected later in November 2026 (Q3 FY 2026-2027); NISE inspection for ALCM enrollment expected in the third week of November 2026.
• Naidupeta ramp guidance — 25-30% CUF expected in December (Q3 FY 2026-2027), scaling to ~70% CUF by end-March (Q4 FY 2026-2027).
• Ingot-wafer plant on a 169-acre Naidupeta site — land, licenses, water allocation and power approvals in place; management hopes to commission Phase 1 by December 2027 (Q3 FY 2027-2028) and Phase 2 (an additional 5 GW, taking total capacity to ~10 GW) by June 2028 (Q1 FY 2028-2029), aligned with ALMM 3.
• ~Rs.2,900 crore of capital work-in-progress — on the 30 September 2026 balance sheet, relates to the cell line not yet commercialized, with commercialization expected in H2 FY 2026-2027; incremental interest and depreciation flow into the P&L over Q3-Q4 FY 2026-2027.
• FY 2026-2027 capex of ~Rs.2,400 crore — ~Rs.700 crore expected over Q3-Q4 FY27, covering residual Naidupeta cell plant payments, battery and aluminum plants, and open access captive projects; management guided FY 2026-2027 depreciation of ~Rs.600 crore (a full-year figure, not quarterly).
• Consolidation thesis — management said pure-play standalone module manufacturing is heading into a very difficult period and backward integration is required; scaled players with ingot-wafer capability will be "the difference between men and boys."

Mix-Driven Blended Margin of ~28%; Transformer Normalization to ~15%

• Q2 FY 2026-2027 blended margin of ~28% — partly a function of higher module share in the mix (analyst observation); management said the mix "will only get better" if SuryaGhar 2.0 and Kusum 2.0 come through.
• Transformer margins fell from ~22% in Q1 to ~12% in Q2 FY 2026-2027 — management expects a normalized margin of ~15% going forward (FY 2026-2027 onward), with the Q1 elevation a one-off benefit from hedged steel and copper inventory.
• Cell order book declined ~Rs.8 billion QoQ — versus ~Rs.4.7 billion of cell revenue booked in Q2 FY 2026-2027; CBO Vinay Rastogi attributed the decline to no new cell orders added (all new orders were DCR or non-DCR modules) and drawdown via production/dispatches; no order cancellations for merchant cell sales were confirmed.
• Captive cell consumption to rise — MD Chiranjeev Singh Saluja said with the new 5.6 GW module line commissioned, the company will prefer captive cell consumption and gradually reduce external solar cell sales.
• Transformer ramp through FY 2029-2030 — 4 GVA of Neo Trafo capacity being commissioned; management expects a gradual ramp to 80-90% of total capacity over the next 3 years (through FY 2029-2030) and expects the business to more than treble revenues over three years; transformer order book at Rs.330 crore.
• Cost pressures on module assembly persist — wafer prices from China moving up and down, silver softened after rising ~3-6 months ago, and recent increases in aluminum, copper and polymer film costs have again impacted module-assembly profitability.

Policy Tailwinds vs. Export-Control Overhang

• Government policy tailwinds cited — CBO Vinay Rastogi said the government is "completely seized" of diversifying the energy mix; over the last one-two months it announced a large green energy corridor scheme and the BPS initiative with the VGF scheme; second versions of Kusum and Surya Ghar Yojana are due for announcement over the next one-two months (by ~Q4 FY 2026-2027).
• China export controls remain a draft — final outcome expected in the next 3-4 weeks, with more details expected on November 15, 2026 (Q3 FY 2026-2027); draft fine print indicates ultra-thin wafer manufacturing equipment would not be allowed, though normal ingot-wafer machines may be allowed. On cell lines, the MD said "on cell line, we are fully covered" — new-age high-technology equipment is already imported.
• BESS: cell-to-pack and pack-to-container scope — no problem with China supplying equipment for these lines (nothing banned); management has deliberately not announced large investments into BESS cell manufacturing, where the supply challenge lies.
• 40% local content confidence — management stated it will comfortably achieve the 40% value addition threshold via cell-to-pack-to-container plus the software element (period unspecified); for the BPS 40% localization guideline, existing capex is sufficient with no additional manufacturing capex required.
• RCT JV and LFP sourcing — the German battery company RCT gives Premier reach into Europe and the US with India-manufactured BESS plus access to its EMS solutions and customer base; no firm LFP cell supply tie-up signed as of the call — the company is working with tier-one Chinese cell manufacturers.
• Demand-supply balance — management said India demand is currently ~50-60 GW (Q2 FY 2026-2027) and should mostly equal or surpass supply for at least another 12-18 months from the call; even at >100 GW national cell capacity by CY27-CY28 (cited by the UBS analyst), average industry output of ~70 GW per annum would keep demand quite strong.
• Analyst risk flag — Amit (UBS) flagged that operating cash flow assumptions over the next 2-3 years, amid profitability pressure during capacity expansion, could pose a serious risk of slowing India's entire renewable capacity framework.

Step-Up Expected from Q3 FY27; Block Deal and QIP Rumors Denied

• "Significant step-up" expected from Q3 FY 2026-2027 onward — driven by the Naidupeta plant ramping up and Sitarampur volumes picking up on increased cell production.
• 10 GW order book to be executed over ~12-14 months — management's timeline (vs. the analyst's 12-month assumption), i.e., through ~Q4 FY 2027-2028.
• US factory advancing — the MD said "Make in America is the answer"; the company is at advanced stages to finalize its US factory location, has a JV partner in place, and targets location finalization in about 12-18 months (spanning FY 2027-2028 into early FY 2028-2029).
• Industry demand outlook — management expects project commissioning to accelerate over the next 6 months, taking industry-wide annual solar capacity addition to around 50 GW AC in FY 2026-2027, surpassing FY 2025-2026 levels; demand pickup expected after December 2026 (Q4 FY 2026-2027) as the BCR regulation kicks in.
• Block deal and QIP rumors denied — MD Chiranjeev Singh Saluja dismissed reports of a GEF block deal (alleged at a 7-10% discount, per DAM Capital's Kunal Shah) as rumors, noting GEF has not appointed Citi as banker; no block deal is planned "in the next couple of quarters or even a couple of years" (through roughly FY 2028-2029); the QIP was only an enabling resolution and no QIP/QIB is planned in the near future (period unspecified).
• Next growth leg undecided — semiconductors remain a "wish list" with no firm plan on timing or partners; near-term priority is completing already-announced capex on committed execution timelines; acquisitions will be looked at "very selectively," with the US and Europe the two main international geographies of interest (no committed timeline given).